SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001225208-21-012492
Filing Date
2021-09-20
Accepted
2021-09-20 18:25:59
Documents
2
Period of Report
2021-09-10

Document Format Files

Seq Description Document Type Size
1 doc3.html 3  
1 doc3.xml 3 2285
2 poa2n.htm EX-24 4128
  Complete submission text file 0001225208-21-012492.txt   7934
Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

IRS No.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address RIVIUM WESTLAAN 142 CAPELLE AAN DEN LJSSEL P7 2909LD
Business Address RIVIUM WESTLAAN 142 CAPELLE AAN DEN LJSSEL P7 2909LD 31-104064349
PF Equity Holdings 2 B.V. (Reporting) CIK: 0001883111 (see all company filings)

State of Incorp.: P7 | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-38693 | Film No.: 211264346